135 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
59
Ending by 2030
Nov 2026
Next term end
51
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2033 · High confidence
Also notable
Ends Mar 2028 · High confidence
Also notable
Ends no later than Jul 2037 · Medium confidence
Also notable
Ends May 2027 · High confidence
Also notable
Ends Jan 2030 · High confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Aug 2034 · High confidence
Also notable
Ends Oct 2031 · Medium confidence
A Method of Increasing Red Blood Cell Levels or Treating Anemia in a Patient
US 8,058,229
Cited by 157 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
Variants Derived from Actriib and Uses Therefor
US 7,842,663
The most cited patent in this portfolio, cited by 195 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Compositions and Methods for Treating Pulmonary Hypertension
US 10,722,558
Cited by 23 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
An Isolated Activin-Binding Actriia Polypeptide Comprising the Seq Id No: 7 and Uses for Promoting Bone Growth
US 7,612,041
Cited by 154 later US patents, top 5% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Methods for Increasing Adiponectin in a Patient in Need Thereof
US 8,138,142
Cited by 134 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Tgf-Beta Superfamily Type I and Type II Receptor Heteromultimers and Uses Thereof
US 10,227,393
Cited by 42 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Transforming Growth Factor Beta Receptor II Fusion Polypeptides
US 9,809,637
Cited by 39 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Polynucleotides Encoding an Actriib Antibody
US 9,624,301
The largest patent family in this portfolio, 8 related applications, renewed at every maintenance window due so far. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 4 to 11, 2026 · next Dec 4
- 3 fees due Jan 23 to 25, 2027 · next Jan 23
- 1 fee due Feb 13, 2027The maintenance fee for Isolated GDF Trap Polypeptide (US 10,377,996) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 3 fees due May 10 to 28, 2027 · next May 10
- 1 fee due Jun 10, 2027The maintenance fee for ALK7 Binding Proteins and Uses Thereof (US 10,501,547) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Compositions and Methods for Treating Spinal Muscular Atrophy (US 11,857,599) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Methods for Treating Vascular Eye Disorders with Actrii Antagonists (US 10,550,170) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 51 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,951,771 | Activin-Actriia Antagonists and Uses for Promoting Bone Growth In force · Medium confidence | In force | Medium confidence | |
| US 8,067,360 | A Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 8,128,933 | A Method of Promoting Bone Growth by an Anti-Activin B Antibody In force · High confidence | In force | High confidence | |
| US 8,486,403 | A Method of Promoting Bone Growth by an Anti-Activin a Antibody In force · High confidence | In force | High confidence | |
| US 8,629,109 | Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Low confidence | In force | Low confidence | |
| US 9,163,075 | AN ISOLATED POLYNUCLEOTIDE THAT ENCODES AN ActRIIa-Fc FUSION POLYPEPTIDE In force · Medium confidence | In force | Medium confidence | |
| US 9,480,742 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | In force | High confidence | |
| US 9,572,865 | Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma In force · High confidence | In force | High confidence | |
| US 10,071,135 | A Method of Identifying an Agent That Promotes Bone Growth or Increases Bone Density In force · Medium confidence | In force | Medium confidence | |
| US 10,239,940 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | In force | High confidence |
Also on record, not counted in the 135: 15 patents in force now held by others · 24 patents ended · 36 applications pending · 116 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.